NASDAQ:PRFX

Tackling the Opioid Epidemic at the Source

PainReform Ltd, listed on the Nasdaq under the ticker “PRFX,” is the developer of PRF-110, an oil-based, viscous, clear solution that is deposited (instilled) directly into a surgical wound bed prior to closure to provide localized and extended post-operative pain relief, thereby reducing the potential need for the use of opiates.

The Company expects to report the results of its groundbreaking Phase 3 trial in mid-2024.

Market Opportunity

The North America post-operative pain treatment market is estimated to reach $16B and $45B world-wide by the end of 2026

The Opioid Epidemic

Most surgical patients receive opioids to manage post-surgical pain
Over 150 million opioid prescriptions were dispensed to American patients annually
Approximately 11.5 million Americans report misusing prescription opioids – 10X the number on heroin
Sadly, many of these people go in for a simple procedure, and after a few days to weeks on pain medicine, they become addicted and can’t stop
6% to 10% of surgical patients discharged with opiate prescriptions develop an opioid dependency
Taking too many prescription opioids can stop a person’s breathing—leading to death
Opiate abuse and addiction cause 70,000 deaths per year in the US and an economic burden of $80B a year
Two out of three drug overdose deaths involve opiates
There is a significant unmet need for long-acting local anesthetic agents in order to spare opioid use, its side effects and reduce hospital length of stay due to complications

Sign up to receive the latest news:

About PRF-110:

PainReform has developed PRF-110, a novel formulation extended-release form of ropivacaine

A viscous clear oil-based solution
Deposited directly into the surgical wound and spreadable over the complete wound surface
Provides localized and extended post-operative analgesia
Designed to reduce the consumption of opioids to manage post-surgical pain

Watch the interview of PainReform CEO Ilan Hadar on “The Big Biz Show”

Proven Clinical Benefits

Effective:

In a Phase 2 clinical study clinical study, PRF-110 provided post-operative pain control for up to 72 hours after a single application
Outperformed market leader in head-to-head comparison

Safe:

PRF-110 was well tolerated
Remains within the surgical site when the skin is closed, without being toxic or proinflammatory
Ropivacaine, the active drug in PRF-110 is a safe and well characterized local anesthetic
The components that make up the remainder of the PRF-110 formulation are classified as GRAS (Generally Regarded as Safe) by the FDA
PRF-110 human safety trials showed no systemic, wound healing or scarring abnormalities

Easy to administer:

Works with standard surgical techniques
Stays in place when placed into a surgical wound bed

FDA Phase III Trial Underway in the U.S.

Recently announced 50% enrollment milestone
On track to announce top-line data by mid-2024

No Long-Term Debt, Clean Capital Structure and Low Public Float

Download the investor presentation:

03/03/2024

Investors Presentation – March 2024

Latest News:

04/18/2024

PainReform Announces Closing of $4 Million Public Offering

04/09/2024

PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

04/02/2024